ALECTOR INC.

Alector announced at the Morgan Stanley Healthcare Conference its transition from a late-stage clinical developer to a preclinical company with five programs on the Alector Brain Carrier (ABC) platform. Lead program AL137 is slated to be given to healthy volunteers for the first time in Q2 2027, with patient dosing to follow in mid-2027. The company highlights higher brain exposure in primate studies, will keep core R&D in-house, and plans partnerships for drug-specific programs. Alector has about $170 million in cash, which is intended to fund operations through 2027 and up to initial proof-of-concept data. » Más en de.investing.com

Alector showcased its transferrin receptor–based brain-carrier platform and lead Alzheimer’s candidate AL137, which is slated to enter a Phase I study with subcutaneous dosing in April. Preclinical data show markedly higher drug concentrations in the brain without a significant drop in red blood cells; AL137 is intended to provide full effector function with reduced anemia risk. The company is also advancing programs targeting tau, alpha-synuclein and GCase and is seeking partnerships for Parkinson’s assets, while Alzheimer programs continue to be developed internally. Alector noted usual development risks; the stock fell during the presentation and the company expects multiple clinical milestones within the next 12 months. » Más en de.investing.com

GSK and Alector have halted joint tests of a dementia drug after a trial flop. The news triggered a marked decline in Alector's share price. No further details about the study or the consequences for Alector's development pipeline were given. » Más en finanzen.net